Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAK-20
- Development stage
- Phase 1
- Lead developer
- Knowledge Research and Innovation Center
- Administration
- Oral
01
Overview
PAK-20 is an investigational herbal compound preparation developed by Knowledge Research and Innovation Center for use in an integrative treatment protocol for COVID-19. In a registered Phase 1 single-group study, it was administered orally as 1 g mixed in 250 mL of soup or meat stock twice daily for up to 12 days, alongside separate interventions including Oniater, asafoetida, herbal tea, and dietary measures. Its chemical composition, individual active constituents, pharmacologic targets, and molecular mechanism of action were not publicly specified in the identified trial registry and publication. ([irct.ir](https://www.irct.ir/trial/52742/pdf))
Beyond the preview
Go deeper on PAK-20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAK-20.